Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

499635 OSC Inhibitor, Ro 48-8071 - CAS 189197-69-1 - Calbiochem

499635
Purchase on Sigma-Aldrich

概述

Replacement Information

重要规格表

CAS #Empirical Formula
189197-69-1C₂₃H₂₇BrFNO₂• C₄H₄O₄

Products

产品目录编号包装 数量 / 包装
499635-10MGCN 玻璃瓶 10 mg
Description
OverviewAn orally bioavailable benzofuranylallylamine compound that acts as a potent, active site targeting, competitive and reversible inhibitor of 2,3-oxidosqualene:lanosterol cyclase activity (OSC; IC50 ~ 6.5 nM against mammalian) and reduces cholesterol synthesis (IC50 ~ 1.5 nM in HepG2 cells) with minimal buildup of both dioxidosqualene and monooxidosqualene. Downregulates 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase mRNA and synthesis, and exerts less adverse effects in animal models than Statins. Shown to preferentially enhance the DNA-binding affinity of mutant p53 and arrest the growth of human breast cancer cells (IC50 ~ 10 µM).
Catalogue Number499635
Brand Family Calbiochem®
Synonyms4ʹ-(6-(Allylmethylamino)hexyloxy)-4-bromo-2ʹ-fluorobenzophenone, fumarate
References
ReferencesThoma, R., et al. 2004. Nature 432, 118.
Peffley, D.M., et al. 1998. Biochem. Pharmacol. 56, 439.
Morand, O.H., et al. 1997. J. Lipid Res. 38, 373.
Product Information
CAS number189197-69-1
FormOff-white solid
Hill FormulaC₂₃H₂₇BrFNO₂• C₄H₄O₄
Chemical formulaC₂₃H₂₇BrFNO₂• C₄H₄O₄
Hygroscopic Hygroscopic
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Purity≥95% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Regulatory Review
Storage +2°C to +8°C
Protect from Light Protect from light
Hygroscopic Hygroscopic
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
产品目录编号 GTIN
499635-10MGCN 04055977199284

Documentation

OSC Inhibitor, Ro 48-8071 - CAS 189197-69-1 - Calbiochem MSDS

职位

物料安全数据表 (MSDS) 

OSC Inhibitor, Ro 48-8071 - CAS 189197-69-1 - Calbiochem 分析证书

标题批号
499635

参考

参考信息概述
Thoma, R., et al. 2004. Nature 432, 118.
Peffley, D.M., et al. 1998. Biochem. Pharmacol. 56, 439.
Morand, O.H., et al. 1997. J. Lipid Res. 38, 373.
数据表

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision17-December-2018 JSW
Synonyms4ʹ-(6-(Allylmethylamino)hexyloxy)-4-bromo-2ʹ-fluorobenzophenone, fumarate
DescriptionAn orally bioavailable benzofuranylallylamine compound that acts as a potent, active site targeting, competitive and reversible inhibitor of 2,3-oxidosqualene:lanosterol cyclase activity (OSC; IC50 ~6.5 nM against mammalian) and reduces cholesterol synthesis (IC50 ~1.5 nM in HepG2 cells) with minimal buildup of both dioxidosqualene and monooxidosqualene. Downregulates 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase mRNA and synthesis, and exerts less adverse effects in animal models than Statins. Shown to preferentially enhance the DNA-binding affinity of mutant p53 and arrest the growth of human breast cancer cells (IC50 ~10 µM).
FormOff-white solid
CAS number189197-69-1
Chemical formulaC₂₃H₂₇BrFNO₂• C₄H₄O₄
Structure formulaStructure formula
Purity≥95% by HPLC
SolubilityH₂O (5 mg/ml)
Storage Protect from light
+2°C to +8°C
Hygroscopic
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Regulatory Review
ReferencesThoma, R., et al. 2004. Nature 432, 118.
Peffley, D.M., et al. 1998. Biochem. Pharmacol. 56, 439.
Morand, O.H., et al. 1997. J. Lipid Res. 38, 373.